Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
Sponsor: Genentech, Inc.
A observational or N/A phase clinical study on Severe Persistent Asthma, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 13 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2022 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Dec 2021 — Mar 2022 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Oct 2020 — Nov 2020 [monthly]
Unknown Status
Status: Enrolling By Invitation → Unknown Status
-
Oct 2018 — Oct 2020 [monthly]
Enrolling By Invitation
-
Jun 2018 — Oct 2018 [monthly]
Enrolling By Invitation
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation
-
Apr 2018 — May 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Aug 2017 [monthly]
Enrolling By Invitation NA
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Rush University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .